98 related articles for article (PubMed ID: 2699507)
1. Lymphomagenesis in Emu-myc transgenic mice does not require transgene rearrangement or mutation of myc exon 1.
Webb E; Barri G; Cory S; Adams JM
Mol Biol Med; 1989 Dec; 6(6):475-80. PubMed ID: 2699507
[TBL] [Abstract][Full Text] [Related]
2. v-myc and v-raf act synergistically to induce B-cell tumors in pristane-primed adult BALBC mice.
Kurie JM; Morse HC; Principato MA; Wax JS; Troppmair J; Rapp UR; Potter M; Mushinski JF
Oncogene; 1990 Apr; 5(4):577-82. PubMed ID: 2183159
[TBL] [Abstract][Full Text] [Related]
3. Lymphomagenesis in E mu-myc transgenic mice can involve ras mutations.
Alexander WS; Bernard O; Cory S; Adams JM
Oncogene; 1989 May; 4(5):575-81. PubMed ID: 2657573
[TBL] [Abstract][Full Text] [Related]
4. The functional basis of c-myc and bcl-2 complementation during multistep lymphomagenesis in vivo.
Marin MC; Hsu B; Stephens LC; Brisbay S; McDonnell TJ
Exp Cell Res; 1995 Apr; 217(2):240-7. PubMed ID: 7698223
[TBL] [Abstract][Full Text] [Related]
5. The human Nramp2 gene: characterization of the gene structure, alternative splicing, promoter region and polymorphisms.
Lee PL; Gelbart T; West C; Halloran C; Beutler E
Blood Cells Mol Dis; 1998 Jun; 24(2):199-215. PubMed ID: 9642100
[TBL] [Abstract][Full Text] [Related]
6. Carcinogen-induced lymphomagenesis in pim-1 transgenic mice: dose dependence and involvement of myc and ras.
Breuer M; Wientjens E; Verbeek S; Slebos R; Berns A
Cancer Res; 1991 Feb; 51(3):958-63. PubMed ID: 1988138
[TBL] [Abstract][Full Text] [Related]
7. Id2 is dispensable for myc-induced lymphomagenesis.
Nilsson JA; Nilsson LM; Keller U; Yokota Y; Boyd K; Cleveland JL
Cancer Res; 2004 Oct; 64(20):7296-301. PubMed ID: 15492249
[TBL] [Abstract][Full Text] [Related]
8. B-cell tumorigenesis in mice carrying a yeast artificial chromosome-based immunoglobulin heavy/c-myc translocus is independent of the heavy chain intron enhancer (Emu).
Palomo C; Zou X; Nicholson IC; Bützler C; Brüggemann M
Cancer Res; 1999 Nov; 59(21):5625-8. PubMed ID: 10554044
[TBL] [Abstract][Full Text] [Related]
9. AID and RAG1 do not contribute to lymphomagenesis in Emu c-myc transgenic mice.
Nepal RM; Zaheen A; Basit W; Li L; Berger SA; Martin A
Oncogene; 2008 Aug; 27(34):4752-6. PubMed ID: 18408759
[TBL] [Abstract][Full Text] [Related]
10. c-myc gene abnormalities in mucosa-associated lymphoid tissue (MALT) lymphomas.
Peng H; Diss T; Isaacson PG; Pan L
J Pathol; 1997 Apr; 181(4):381-6. PubMed ID: 9196434
[TBL] [Abstract][Full Text] [Related]
11. Clustered mutations in the second exon of the MYC gene in sporadic Burkitt's lymphoma.
Yano T; Sander CA; Clark HM; Dolezal MV; Jaffe ES; Raffeld M
Oncogene; 1993 Oct; 8(10):2741-8. PubMed ID: 8397370
[TBL] [Abstract][Full Text] [Related]
12. A non-transgenic mouse model for B-cell lymphoma: in vivo infection of p53-null bone marrow progenitors by a Myc retrovirus is sufficient for tumorigenesis.
Yu D; Thomas-Tikhonenko A
Oncogene; 2002 Mar; 21(12):1922-7. PubMed ID: 11896625
[TBL] [Abstract][Full Text] [Related]
13. Integration of a c-myc transgene results in disruption of the mouse Gtf2ird1 gene, the homologue of the human GTF2IRD1 gene hemizygously deleted in Williams-Beuren syndrome.
Durkin ME; Keck-Waggoner CL; Popescu NC; Thorgeirsson SS
Genomics; 2001 Apr; 73(1):20-7. PubMed ID: 11352562
[TBL] [Abstract][Full Text] [Related]
14. Acceleration of B-lymphoid tumorigenesis in E mu-myc transgenic mice by v-H-ras and v-raf but not v-abl.
Langdon WY; Harris AW; Cory S
Oncogene Res; 1989; 4(4):253-8. PubMed ID: 2549487
[TBL] [Abstract][Full Text] [Related]
15. H-2/myc, E mu/myc, and c-myc transgenic mice: potent sources of early hematopoietic cell lines.
Roland J; Morello D
Cell Growth Differ; 1993 Nov; 4(11):891-900. PubMed ID: 8297795
[TBL] [Abstract][Full Text] [Related]
16. Towards a therapeutic inhibition of dystrophin exon 23 splicing in mdx mouse muscle induced by antisense oligoribonucleotides (splicomers): target sequence optimisation using oligonucleotide arrays.
Graham IR; Hill VJ; Manoharan M; Inamati GB; Dickson G
J Gene Med; 2004 Oct; 6(10):1149-58. PubMed ID: 15386737
[TBL] [Abstract][Full Text] [Related]
17. Moloney murine leukemia virus infection accelerates lymphomagenesis in E mu-bcl-2 transgenic mice.
Shinto Y; Morimoto M; Katsumata M; Uchida A; Aozasa K; Okamoto M; Kurosawa T; Ochi T; Greene MI; Tsujimoto Y
Oncogene; 1995 Nov; 11(9):1729-36. PubMed ID: 7478600
[TBL] [Abstract][Full Text] [Related]
18. Mouse and rat B-myc share amino acid sequence homology with the c-myc transcriptional activator domain and contain a B-myc specific carboxy terminal region.
Asker CE; Magnusson KP; Piccoli SP; Andersson K; Klein G; Cole MD; Wiman KG
Oncogene; 1995 Nov; 11(10):1963-9. PubMed ID: 7478514
[TBL] [Abstract][Full Text] [Related]
19. Conservation and expression of an alternative 3' exon of Runx2 encoding a novel proline-rich C-terminal domain.
Terry A; Kilbey A; Vaillant F; Stewart M; Jenkins A; Cameron E; Neil JC
Gene; 2004 Jul; 336(1):115-25. PubMed ID: 15225881
[TBL] [Abstract][Full Text] [Related]
20. Characterization of hprt splicing mutations induced by the ultimate carcinogenic metabolite of benzo[a]pyrene in Chinese hamster V-79 cells.
Hennig EE; Conney AH; Wei SJ
Cancer Res; 1995 Apr; 55(7):1550-8. PubMed ID: 7882364
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
